460 results about "Hypoglycemic drugs" patented technology

A controlled release pharmaceutical tablet containing antihyperglycemic drug and a hypoglycemic drug that does not contain an expanding or gelling polymer layer and comprising a core containing the antihyperglycemic drug and the hypoglycemic drug, a semipermeable coating membrane surrounding the core and at least one passageway in the membrane to allow the drugs to be released from the core.

The invention discloses fuscoporia obliqua active ingredients capable of lowering blood sugar and a preparation method and application of the fuscoporia obliqua active ingredients. The preparation method takes fuscoporia obliqua fruit body as raw material and comprises the following steps: respectively extracting, filtering and concentrating the fuscoporia obliqua fruit body with normal temperature water and high temperature water; adding alcohol into concentrate and depositing to obtain crude polysaccharide; respectively pouring the polysaccharide extracted with normal temperature water and the crude polysaccharide extracted with high temperature water to flow through a (diethylaminoethanol) DEAE-52 cellulose column; carrying out subsection elution by using distilled water and NaCl solutions with different concentrations; and collecting stepwise elution peak sugar solution. Internal blood sugar reduction activity experiment shows that 0.2mol/L NaCl-section eluted sugar of the crude polysaccharide extracted with normal temperature water and 0.2mol/L NaCl-section eluted sugar of the crude polysaccharide extracted with high temperature water both have obvious blood sugar reduction activity, same blood sugar reduction activity with the blood sugar reduction medicine of metformin hydrochloride, and no obvious toxic or side effect.

The invention discloses a recombined human hyaluronidase, a production and purification method and preparations of the recombined human hyaluronidase, a use method and application. Recombined human hyaluronidase PH20 or human hyaluronidase human albumin fusion protein PH20-HSA or human hyaluronidase human immunoglobulin IgG2Fc fragment fusion protein PH20-IgFc is adopted by the recombined human hyaluronidase and used in the mucosa or the surface of the skin. The preparations of the recombined human hyaluronidase can be made into different types such as membrane preparations, spray preparations, lotion and freeze-dried powder spray and used for skin infiltration promotion of beauty nutrient substances, skin mucosa infiltration promotion of surface anesthetic, infiltration promotion of skin disease therapeutic medicine, mucosa infiltration promotion of biological tranquillizer, mucosa skin infiltration promotion of growth factors, mucosa infiltration promotion of hypoglycemic drug, mucosa nasal cavity infiltration promotion of nervous centralis nutrient substances and the like.

The present invention relates to a new-type hypoglycemic medicine composition. Said new-type hypoglycemic medicine composition contains biguanide hypoglycemic medicine or its medicinal salt with effective dose, thiazolidione hypoglycemic medicine or its medicinal salt with effective dose, vitamins B with effective dose and medicinal carrier or excipient. Said invention also provides the application of said medicine composition in preparation of medicine for preventing and/or curing diabetes and its complication.

The invention relates to a hypoglycemic drug and a composition, and particularly relates to a compound shown in a formula I in the specification or a solvate thereof, wherein the structure is shown in the specification. The invention further relates to a drug composition comprising the compound, and applications of the compound and the drug composition. The compound or the composition is an excellent hypoglycemic drug.

The invention belongs to the field of medical biology, and particularly relates to a method for extracting a konjac polypeptide extract from konjac flying powder, the konjac polypeptide extract obtained by the method and an application of the konjac polypeptide extract. In order to increase the content of konjac polypeptide in the konjac polypeptide extract, the optimized extraction technology provided by the invention adopts a complex enzyme to perform enzymolysis on the protein extraction liquid of the konjac flying powder; in the finally obtained konjac polypeptide extract, the content of konjac polypeptide is as high as 85-97%, and the molecular weight of the konjac polypeptide is 350-3500Da. Moreover, the invention also provides an application of the konjac polypeptide extract in preparing a medicine for treating diabetes and diabetic complications as well as a hypoglycemic medicinal composition containing the konjac polypeptide extract. In a word, the konjac polypeptide extract and the medicinal composition thereof provided by the invention have good prospect in medicine.

The invention relates to a hypoglycemic medicine and a composition, and in particular relates to a compound as shown in the formula I or a solvate thereof. The structure of the composition is described in the specification. The invention further relates to a medicine composition comprising the compound and application of the medicine composition and the compound. The compound or the composition is an excellent hypoglycemic medicine.

There exists a strong desire both for pharmaceutical compositions which rapidly exhibit pharmacological effects without an increase in the size of the dosage form or a decline in quality due to interactions between a pharmaceutically active ingredient and the disintegrant, and also for a method of preparing such pharmaceutical compositions. Such a desire is especially acute with regard to, for example, preparations which contain a drug such as an analgesic or a quick-acting hypoglycemic drug that requires the rapid appearance of pharmacological effects following administration, preparations which have a high content of the pharmaceutically active ingredient, and preparations which contain two or more different pharmaceutically active ingredients. Thus, the object of the present invention is to improve the disintegratability of the pharmaceutical compositions without increasing the size of the dosage form and without a decline in quality due to interactions between the pharmaceutically active ingredient and the disintegrant. The present invention provides a method for preparing a pharmaceutical composition having a rapid disintegration time, comprising: blending, in the pharmaceutical composition containing a pharmaceutically active ingredient, at least one disintegrant and at least one water-soluble salt having a pH being from 3 to 9 in an aqueous solution of 2.5% concentration. The invention also provides a premix composition obtained by the preliminary mixture of a disintegrant with a water-soluble inorganic salt having a pH of from 3 to 9 in an aqueous solution of 2.5% concentration.

The present invention discloses a method for preparing a Camellia nitidissima Chi lipid-lowering and hypoglycemic agent. Active components such as tea polysaccharides, tea polyphenols, and flavones are extracted from Camellia nitidissima Chi and purified, which are then mixed with pharmaceutical excipients such as hydroxypropyl methyl cellulose, polyvinylpyrrolidone, and triethyl citrate to prepare various pills, tablets, capsules, granules, etc. including sustained release agents and controlled release agents. Thereby, clinical or health care medicine effects of the Camellia nitidissima Chi lipid-lowering and hypoglycemic agent are improved, a dosing frequency is reduced, interference of impurities with the medicine effect is eliminated, relative bioavailability and safety of the active components of the Camellia nitidissima Chi lipid-lowering and hypoglycemic agent in a human body are enhanced, and compliance of a patient is improved.

The invention relates to a sugar-lowering drug composition and application thereof. The composition comprises 1) medicinal dosage of vildagliptin, 2) medicinal dosage of any one or combination of thiazolidinedione sugar-lowering drugs or medicinal salt thereof, sulfonylurea sugar-lowering drugs or medicinal salt thereof or biguanide sugar-lowering drugs or medicinal salt thereof and 3) B vitamins. The invention relates to application of the sugar-lowering drug composition to preparing the drugs for treating and/or controlling diabetes or diabetic complications. The composition can effectively overcome the defect that type 2 diabetes can not be controlled by singly taking the commonly used sugar-lowering drugs or vildagliptin in the prior art and simultaneously addition of the B vitamins is conductive to enhancing the treatment effect of the drug, effectively controlling the blood sugar, protecting the endothelial cell functions in a synergic manner, slowing rising of plasma homocysteine of the diabetes patients, especially the diabetes patients associated with chronic complications and reducing the diabetic complications.

The invention provides a thrombin activity based chimeric peptide with double targeting effects, a preparation method and an application thereof. The chimeric peptide provided by the invention contains three segments: segment 1 has an amino acid sequence having 20th to 90th amino acid from N-terminal of HMGB1 protein; segment 2 has an amino acid sequence of Exendin-4 protein; and segment 3 which contains cleavage sites of thrombin and dipeptidyl peptidase is a junction fragment of segment 1 and segment 2. According to the preparation method provided by the invention, the thrombin activity based chimeric peptide with double targeting effects can be obtained by synthesis of a polypeptide synthesis technology or construction of an expression vector which contains nucleotide sequence encoding the chimeric peptide, expression of the protein in a gene engineering strain and purification of the protein. The chimeric peptide provided by the invention has double targeting effects of inhibiting inflammatory response and decreasing blood glucose, and can be applied in the preparation of anti-inflammatory and/or hypoglycemic drugs.

The invention relates to application of total flavonoids of lilac daphne root extracted from a lilac daphne plant to preparation of a medicament for reducing blood sugar. The total flavonoids of lilac daphne root, which is disclosed by the invention, respectively represents remarkable activity of reducing blood sugar at each dosage; and the total flavonoids of lilac daphne root can be used for preparing a medicament or health-card food for preventing or treating hyperglycemia symptom.

The invention discloses a new C-aryl glycosidase SGLT2 (sodium glucose transporter type-2) inhibitor, relates to the field of medicines associated with diabetes, and in particular relates to a new C-aryl glycosidase derivative shown as the general formula (I), a preparation method thereof, compositions thereof, and use thereof in preparing hypoglycemic drugs. The C-aryl glucoside derivative has excellent effect of promoting urine discharge and in-vivo hypoglycemic activity, and compounds with equal or better in-vivo hypoglycemic activity than that of dapagliflozin are screened out, and can be used for the prevention or treatment of diabetes.

The invention relates to a dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method, which can industrially prepare both liposome medicine-carrying injections and liposome medicine-carrying oral preparations by utilizing uniform prescriptions, technologies and devices. The invention provides a mole-ratio prescription of various components and materials for preparing liposome medicine-carrying preparations, and provides a technology for preparing nanoliposome lyophilization injections and liposome oral preparations. The invention also provides 20 embodiments for preparing liposome medicine-carrying preparations: an embodiment for preparing anti-gastric-ulcer liposome medicine-carrying preparations, an embodiment for preparing antibiosis and anti-fungus liposome medicine-carrying preparations, an embodiment for preparing anti-tumor liposome medicine-carrying preparations, an embodiment for preparing anti-viral liposome medicine-carrying preparations, an embodiment for preparing anti-emetic liposome medicine-carrying preparations, an embodiment for preparing nutrition-supplement liposome medicine-carrying preparations and an embodiment for preparing anti-diabetics and cardio- and cerebro-vascular drug liposome medicine-carrying preparations.

The invention relates to a newly-developed medicine compound for diabetes which contains sulfonylureas drug for diabetes or a bioactive metabolite of the sulfonylureas drug for diabetes or pharmaceutical salt of the sulfonylureas drug for diabetes, and thiazolidinedione drug for diabetes or pharmaceutical salt and vitamin B of the thiazolidinedione drug for diabetes. The compound contains the sulfonylureas drug for diabetes of therapy dose or the bioactive metabolite of the sulfonylureas drug for diabetes or the pharmaceutical salt of the sulfonylureas drug for diabetes, the thiazolidinedione drug for diabetes of therapy dose or the pharmaceutical salt and therapy dose of vitamin B of the thiazolidinedione drug for diabetes or compound which is related to the thiazolidinedione drug for diabetes and has similar bioactivity and pharmaceutical carrier or excipient. The invention also relates to the purpose of the compound in preparation of drug for treating diabetes or preventing diabetes complication, belonging to the pharmaceutical field.

The invention discloses a guanidine hypoglycemic drug-polysaccharide conjugate, as well as a preparation method and application thereof. The conjugate is formed by connecting primary amine on a guanidine drug and the aldehyde group on oxidative polysaccharide through a schiff base bond. Compared with an existing guandine hypoglycemic drug, on the one hand, the conjugate can be used as a polymeric prodrug for reducing blood glucose, so that the pharmacologic action is strengthened, few adverse responses exist, and the safety is higher; on the other hand, the conjugate can be combined with therapeutic genes for treating diabetes mellitus, in particular obese diabetic, and the curative effect of the conjugate on cellular level and animal pattern are better than those of active compounds and therapeutic gene. The results prove that the guanidine hypoglycemic drug-polysaccharide conjugate has tremendous potential in the aspect of drug combined gene therapy of diabetes mellitus due to the excellent biocompatibility and effective gene transfer efficiency; the synthesizing and preparing method is simple, the process is mature, and the yield is high.

The invention discloses a preparation method of a mulberry bark extract with blood glucose reducing effect, which comprises the steps of: peeling mulberry barks from mulberry twigs, drying, and pulverizing to obtain mulberry bark powder; extracting with 10-95% ethanol aqueous solution at 60-90 DEG C under reflux for 1-24 hours, filtering the obtained extractive solution to remove insoluble substances and residues, and concentrating with a rotary concentrating machine to obtain a concentrated solution; adding 2% papain, and allowing enzymolysis under shaking at 60 DEG C for 2 hours; removing proteins with a chloroform/n-butanol mixture solution; adding 1% activated carbon for decolorizing, filtering to obtain a straw yellow colored clear mulberry bark active extractive solution, and spraying drying or vacuum freeze drying to obtain a powdered mulberry bark extract. The inventive preparation method directly extracts a hypoglycemic drug with ALPHA-glycosidase inhibitor activity from the single medicinal raw material mulberry barks peeled from mulberry twigs; and has the advantages of simple process, low cost, and high efficiency.

The invention discloses a mangiferin single-site derivative, which is as shown in a formula I-I, wherein definition of R6 is specified in the specification. In addition, the invention further discloses a preparation method of the derivative. The derivative is capable of inhibiting diabete-related enzymes such as PTP1B and alpha-glycosidase, so as to play a role of reducing blood sugar; meanwhile, a mangiferin compound has wide physiological activity; and side effects on a human body caused by traditional hypoglycemic drugs can be avoided.

The invention relates to a refining technology of mycelia polysaccharides of selenium-enriched hericium erinaceus. The mycelia polysaccharides are greatly different from the common hericium erinaceus polysaccharides in structural composition. A few of related researches of the hericium erinaceus polysaccharides are reported. The hericium erinaceus mycelia produced by the invention are utilized, selenium element is added in the growth process of the mycelia, and then the mycelia polysaccharides are extracted, so as to take a biological active effect of a mycelium polysaccharide substance of the hericium erinaceus, and exert the microelement regulating function of the selenium element as well. The mycelia polysaccharides of the selenium-enriched hericium erinaceus have broad application prospects in the aspects such as food antimicrobial additives, hypoglycemic drug additives and healthcare products for body immune regulation.

The invention discloses a preparation method of sargassum oligosaccharide. The preparation method comprises the steps that fine polysaccharide obtained through degreasing and deproteinizing of sargassum is taken as a raw material, ultrasonic treatment is utilized, alginate lyase, mannase, xylanase and pectinase are sequentially added to perform enzymolysis on the polysaccharide, the polysaccharide which is not degraded fully is removed through an ethyl alcohol sedimentation method, supernate is centrifuged and screened by a molecular sieve to obtain retained matter, freeze drying is performed, and the sargassum oligosaccharide is prepared. The prepared sargassum oligosaccharide has the high inhibitory activity on alpha-glucosidase, the IC50 value is 4.82 mg/mL, the dose dependency is presented, and meanwhile the obvious promoting effect on glucose consumption of insulin-resistant HepG2 cells is achieved. According to the preparation method, the non-specific commercial enzymes are adopted, the process route is simple and reasonable, the method is suitable for industrialization, the preparation amount of the hypoglycemic active oligosaccharide is increased, and meanwhile the enzyme consumption and production cost are reduced; the method is an effective method for preparing the sargassum oligosaccharide and can be applied to hypoglycemic drugs, health care products and food.